Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average) (2018 - 2026)

Compass Therapeutics has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $186.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $186.4 million, up 34.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $186.4 million (up 34.84% YoY), and the FY2025 annual result was $157.7 million, up 14.78% from the prior year.
• Shares Outstanding (Weighted Average) came in at $186.4 million for Q1 2026 at Compass Therapeutics, up from $157.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $186.4 million in Q1 2026 to a low of $100.9 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $136.6 million (2024), against an average of $132.5 million.
• Across the five-year window, Shares Outstanding (Weighted Average) jumped 96.55% in 2022 and advanced 0.85% in 2025, its largest moves.
• Compass Therapeutics' Shares Outstanding (Weighted Average) stood at $105.2 million in 2022, then rose by 20.76% to $127.0 million in 2023, then grew by 8.15% to $137.4 million in 2024, then climbed by 14.78% to $157.7 million in 2025, then grew by 18.2% to $186.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $186.4 million (Q1 2026), $157.7 million (Q4 2025), and $168.8 million (Q3 2025), per Business Quant data.